CGChristoph G. W. Gertzen

Christoph G. W. Gertzen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christoph G. W. Gertzen has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ATPLyzer – An advanced ratiometric multi-colour biosensor for long-term monitoring of ATP dynamics

    by Athanasios Papadopoulos, Christian F. Kaiser, Patrick Schlumpberger, Jacqueline Eßer, Jens Reiners, Christoph G.W. Gertzen, Guido Grossmann, Sander H.J. Smits

    Adenosine triphosphate (ATP) is a central molecule in cellular metabolism, serving as the primary energy currency that links catabolic and anabolic pathways. Monitoring intracellular ATP in vivo is essential for understanding the dynamics of metabolic states, as well as intracellular functions and intercellular interactions in health and disease. We report the design and application of ATPLyzer, a series of genetically encoded, ratiometric biosensors for the monitoring of ATP levels in living cells. The matryoshka design consists of an ATP-binding cassette linked to a circularly permutated GFP coupled with an internal large stokes shift reference fluorophore, allowing for single-wavelength excitation and ratiometric output. This design overcomes limitations of conventional biosensors, reliance on dual excitation wavelengths, and susceptibility to photobleaching. Multi-colour ATPLyzer variants with different dissociation constants were characterized in vitro , exhibiting high specificity for ATP over ADP. Monitoring ATP in Escherichia coli confirmed in vivo utility and revealed growth-phase and carbon-supply-dependent ATP dynamics. The ATPLyzer biosensor offers a robust and tuneable tool for minimally invasive, time-resolved monitoring of intracellular ATP dynamics.

  • Open Access

    Small-molecule inhibitor of C‑terminal HSP90 dimerization modulates autophagy and functions synergistically with mTOR inhibition to kill cisplatin-resistant cancer cells

    by Céline David, Yadong Sun, Vitalij Woloschin, Melina Vogt, Niklas Dienstbier, Annabelle Friedrich, Karina S. Krings, David Schlütermann, Lena Berning, Beate Lungerich, et al.

    A major obstacle for the successful treatment of cancer is the presence or development of resistance mechanisms toward therapeutic intervention. In urothelial cancer, cisplatin-based regimens are still routinely employed, and multiple pathways contribute to chemoresistance. Since the identification of heat shock protein 90 (HSP90) as potential cancer target, various HSP90 inhibitors have been developed and evaluated in clinical trials. However, limited efficacy has been observed, mainly caused by dose-limiting toxicity and the concomitant induction of a cytoprotective heat shock response (HSR). To avoid this effect, inhibitors targeting the C-terminal domain (CTD) of HSP90 that do not elicit an HSR have been put forward. Additionally, the crosstalk between autophagy and HSP90 is currently being explored, since both processes work together in proteostasis, and the modulation of autophagy might be helpful in order to improve the efficacy of HSP90 inhibitors. We demonstrate that the second-generation small-molecule inhibitor VWK147 targeting HSP90 CTD dimerization induces cell death in both cisplatin-sensitive and cisplatin-resistant urothelial carcinoma cells. The treatment with VWK147 in these cells led to the destabilization of classical HSP90 client proteins without triggering an HSR. Additionally, we observe that VWK147 re-sensitizes resistant urothelial carcinoma cells to cisplatin and—in combination with mTOR inhibition—synergistically kills cisplatin-sensitive and -resistant cells, in contrast to what is observed upon treatment with the N-terminal domain-targeting HSP90 inhibitor 17-AAG. This synergy may be explained by VWK147-mediated inhibition of late autophagy events, and thus a blockade of autophagic flux. Finally, we also observed that VWK147 induces non-canonical LC3 lipidation, indicating that this compound exerts a broader effect on ion balance or pH of the endolysosomal system. VWK147 is a promising inhibitor that targets the C-terminal dimerization of HSP90 and simultaneously exhibits autophagy-modulating effects. This compound could potentially be an effective option for improving anti-cancer therapies and/or overcoming treatment resistance.


  • A novel biosensor for ferrous iron developed via CoBiSe: A computational method for rapid biosensor design

    by Athanasios Papadopoulos, Manuel T. Anlauf, Jens Reiners, Seung-Hyun Paik, Thomas Drepper, Aileen Krüger, Benita Lückel, Michael Bott, Julia Frunzke, Holger Gohlke, et al.

    BioStudies – one package for all the data supporting a study

  • Open Access

    A novel biosensor for ferrous iron developed via CoBiSe: A computational method for rapid biosensor design

    by Athanasios Papadopoulos, Manuel T. Anlauf, Jens Reiners, Sueng-Hyun Paik, Aileen Krüger, Benita Lückel, Michael Bott, Thomas Drepper, Julia Frunzke, Holger Gohlke, et al.

    Genetically encoded biosensors enable monitoring of metabolite dynamics in living organisms. We present CoBiSe, a computational approach using Constraint Network Analysis to identify optimal insertion sites for reporter modules in molecular recognition elements (MREs). Applied to the iron-binding protein DtxR from Corynebacterium glutamicum , CoBiSe identified a flexible connective loop (residues 138-150) for inserting the reporter module, resulting in IronSenseR, a novel ratiometric biosensor for ferrous iron (Fe²⁺). IronSenseR demonstrates high specificity for Fe²⁺ with dissociation constants of 1.55 ± 0.08 µM (FeSO 4 ) and 2.44 ± 0.28 µM (FeCl 2 ), while showing no binding to Fe³⁺ and other divalent cations. In vivo assessment in Escherichia coli , Pseudomonas putida and Corynebacterium glutamicum confirmed IronSenseR’s capability to detect changes in the intracellular iron pool. The creation of IronSenseR underlines that, by reducing search space and eliminating labor-intensive screening, CoBiSe streamlines biosensor development and enables precise creation of next-generation biosensors for diverse metabolites.

  • Open Access

    The coming of age of DNA‐based catalysts for therapeutic applications

    by Robert Hesse, Christoph G. W. Gertzen, Jessica Felice Schmuck, Justin Darvin Böcker, Piyush Pandey, Tobias Behn, Christopher Ruth, Detlev Riesner, Stephanie Kath‐Schorr, Philipp A. Lang, et al.

  • Open Access

    Structural insights into the substrate binding mechanism of the class I dehydratase MadB

    by C. Vivien Knospe, Julio Ortiz, Jens Reiners, Alexej Kedrov, Christoph G. W. Gertzen, Sander H. J. Smits, Lutz Schmitt

    In the battle against antimicrobial resistance, lantibiotics have emerged as promising new sources for antimicrobial drugs. Their exceptional stability is due to characteristic modifications termed (methyl-)lanthionine rings. Genome mining efforts have identified hundreds of lantibiotics by detecting gene operons, so-called biosynthetic gene clusters (BGC), which encode cysteine-rich peptides (30-50 amino acids in size) and enzymes responsible for dehydration and cyclization, catalyzing the post-translational ring formation. One such identified, class I lantibiotic is maddinglicin from Clostridium maddingley. Here, we present single particle cryo-EM structures of the dehydratase MadB in both, its apo-state and in complex with a leader peptide of maddinglicin, revealing a distinct conformational change upon substrate binding. Small-angle X-ray scattering studies elucidate the substrate binding site for the C-terminal part of maddinglicin. Furthermore, a substrate specificity analysis was performed highlighting a critical stretch of amino acids within the maddinglicin leader sequence that is crucial for binding. Here, we provide molecular insights into the conformational changes, principles of substrate recognition and ligand:protein stoichiometry of a class I lantibiotic dehydratase.


  • Open Access

    Small-molecule inhibitor of C-terminal HSP90 dimerization modulates autophagy and functions synergistically with mTOR inhibition to kill cisplatin-resistant cancer cells

    by Céline David, Yadong Sun, Vitalij Woloschin, Melina Vogt, Niklas Dienstbier, David Schlütermann, Lena Berning, Beate Lungerich, Annabelle Friedrich, Seda Akgün, et al.

    Background A major obstacle for the successful treatment of cancer is the primary presence or development of resistance mechanisms toward therapeutic intervention. In urothelial cancer, cisplatin-based regimens are still routinely employed, and multiple cellular pathways contribute to chemoresistance. Since the identification of heat shock protein 90 (HSP90) as potential cancer target, various HSP90 inhibitors (HSP90i) have been developed and evaluated in clinical trials. However, limited efficacy has been observed, mainly caused by dose-limiting toxicity and the concomitant induction of a cytoprotective heat shock response (HSR). To avoid this effect, inhibitors targeting the C-terminal domain (CTD) of HSP90 that do not elicit an HSR have been put forward. Additionally, the crosstalk between autophagy and HSP90 is currently being explored, since both processes work together in proteostasis, and the modulation of autophagic responses might be helpful in order to improve the efficacy of HSP90 inhibitors. Methods The second-generation small-molecule inhibitor VWK147 targeting HSP90 CTD dimerization was synthesized and characterized in detail by biochemical cell-free and cellular assays and molecular modeling. Specifically, HSP90 inhibition, cell viability, and autophagy were monitored in mono- and combined treatments. Results We demonstrate that VWK147 induces cell death in both cisplatin-sensitive and cisplatin-resistant urothelial carcinoma cells. The treatment with VWK147 in these cells led to the destabilization of classical HSP90 client proteins without triggering an HSR. Additionally, we observe that VWK147 re-sensitizes resistant urothelial carcinoma cells to cisplatin and—in combination with mTOR inhibition—synergistically kills cisplatin-sensitive and -resistant cells, in contrast to what is observed upon treatment with the N-terminal domain-targeting HSP90 inhibitor 17-AAG. This synergy may be explained by VWK147-mediated inhibition of late autophagy events, and thus a blockade of autophagic flux. Finally, we also observed that VWK147 induces non-canonical LC3 lipidation, indicating that this compound possibly exerts a broader effect on ion balance or pH of the endolysosomal system. Conclusion VWK147 is a promising inhibitor that targets the C-terminal dimerization of HSP90 and simultaneously exhibits autophagy-modulating effects. This compound could potentially be an effective option for improving anti-cancer therapies and/or overcoming treatment resistance.

  • Open Access

    Synthesis and Biological Evaluation of Novel MB327 Analogs as Resensitizers for Desensitized Nicotinic Acetylcholine Receptors after Intoxication with Nerve Agents

    by Tamara Bernauer, Valentin Nitsche, Jesko Kaiser, Christoph G.W. Gertzen, Georg Höfner, Karin V. Niessen, Thomas Seeger, Dirk Steinritz, Franz Worek, Holger Gohlke, et al.

    Poisoning with organophosphorus compounds, which can lead to a cholinergic crisis due to the inhibition of acetylcholinesterase and the subsequent accumulation of acetylcholine (ACh) in the synaptic cleft, is a serious problem for which treatment options are currently insufficient. Our approach to broadening the therapeutic spectrum is to use agents that interact directly with desensitized nicotinic acetylcholine receptors (nAChRs) in order to induce functional recovery after ACh overstimulation. Although MB327, one of the most prominent compounds investigated in this context, has already shown positive properties in terms of muscle force recovery, this compound is not suitable for use as a therapeutic agent due to its insufficient potency. By means of in silico studies based on our recently presented allosteric binding pocket at the nAChR, i.e. the MB327-PAM-1 binding site, three promising 4-aminopyridinium ion-substituted MB327 analogs (PTM0056, PTM0062 and PTM0063) were identified. In this study, we present the synthesis and biological evaluation of a series of new 4-aminopyridinium ion-substituted analogs of the aforementioned compounds (PTM0064-PTM0072), as well as hydroxy-substituted analogs of MB327 (PTMD90-0012 and PTMD90-0015) designed to substitute energetically unfavorable water clusters identified during molecular dynamics simulations. The compounds were characterized in terms of their binding affinity towards the aforementioned binding site by applying the UNC0642 MS Binding Assays and in terms of their muscle force reactivation in rat diaphragm myography. More potent compounds were identified compared to MB327, as some of them showed a higher affinity towards MB327-PAM-1 and also a higher recovery of neuromuscular transmission at lower compound concentrations. To improve the treatment of organophosphate poisoning, direct targeting of nAChRs with appropriate compounds is a key step, and this study is an important contribution to this research.

  • Open Access

    MS Binding Assays with UNC0642 as reporter ligand for the MB327 binding site of the nicotinic acetylcholine receptor

    by Valentin Nitsche, Georg Hoefner, Jesko Kaiser, Christoph G.W. Gertzen, Thomas Seeger, Karin V. Niessen, Dirk Steinritz, Franz Worek, Holger Gohlke, Franz F. Paintner, et al.

    Intoxications with organophosphorus compounds (OPCs) based chemical warfare agents and insecticides may result in a detrimental overstimulation of muscarinic and nicotinic acetylcholine receptors evolving into a cholinergic crisis leading to death due to respiratory failure. In the case of the nicotinic acetylcholine receptor (nAChR), overstimulation leads to a desensitization of the receptor, which cannot be pharmacologically treated so far. Still, compounds interacting with the MB327 binding site of the nAChR like the bispyridinium salt MB327 have been found to re-establish the functional activity of the desensitized receptor. Only recently, a series of quinazoline derivatives with UNC0642 as one of the most prominent representatives has been identified to address the MB327 binding site of the nAChR as well. In the present study, MS Binding Assays utilizing UNC0642 as a reporter ligand have been established. Thus, the binding of UNC0642 towards Torpedo -nAChR has been characterized in MS saturation and competition experiments. According to the results, UNC0642 addresses the MB327 binding site of the Torpedo -nAChR. This conclusion is further supported by the outcome of ex vivo studies performed with poisoned rat diaphragm muscles as well as by in silico studies predicting the binding mode of the most affine analog UNC0646 in the recently proposed binding site of MB327 (MB327-PAM-1). The new MS Binding Assays based on the commercially available reporter ligand UNC0642 as one of the most affine ligands for the MB327 binding site are a potent and valuable alternative to established assays.


  • Open Access

    DNA-binding and protein structure of nuclear factors likely acting in genetic information processing in the Paulinella chromatophore

    by Luis Macorano, Taniya M. Binny, Tobias Spiegl, Victoria Klimenko, Anna Singer, Linda Oberleitner, Violetta Applegate, Sarah Seyffert, Anja Stefanski, Lothar Gremer, et al.

    The chromatophores in Paulinella are evolutionary-early-stage photosynthetic organelles. Biological processes in chromatophores depend on a combination of chromatophore and nucleus-encoded proteins. Interestingly, besides proteins carrying chromatophore-targeting signals, a large arsenal of short chromatophore-targeted proteins (sCTPs; <90 amino acids) without recognizable targeting signals were found in chromatophores. This situation resembles endosymbionts in plants and insects that are manipulated by host-derived antimicrobial peptides. Previously, we identified an expanded family of sCTPs of unknown function, named here “DNA-binding (DB)-sCTPs”. DB-sCTPs contain a ~45 amino acid motif that is conserved in some bacterial proteins with predicted functions in DNA processing. Here, we explored antimicrobial activity, DNA-binding capacity, and structures of three purified recombinant DB-sCTPs. All three proteins exhibited antimicrobial activity against bacteria involving membrane permeabilization, and bound to bacterial lipids in vitro. A combination of in vitro assays demonstrated binding of recombinant DB-sCTPs to chromatophore-derived genomic DNA sequences with an affinity in the low nM range. Additionally, we report the 1.2 Å crystal structure of one DB-sCTP. In silico docking studies suggest that helix α2 inserts into the DNA major grove and the exposed residues, that are highly variable between different DB-sCTPs, confer interaction with the DNA bases. Identification of photosystem II subunit CP43 as a potential interaction partner of one DB-sCTP, suggests DB-sCTPs to be involved in more complex regulatory mechanisms. We hypothesize that membrane binding of DB-sCTPs is related to their import into chromatophores. Once inside, they interact with the chromatophore genome potentially providing nuclear control over genetic information processing.